CYP450 genotype/phenotype concordance in Mexican Amerindian indigenous populations–where to from here for global precision medicine?
F de Andrés, M Sosa-Macías, BPL Ramos… - OMICS: A Journal of …, 2017 - liebertpub.com
Global precision medicine demands characterization of drug metabolism and phenotype
variation in diverse populations, including the indigenous societies. A related question is the …
variation in diverse populations, including the indigenous societies. A related question is the …
Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism
P Dorado, I González, MEG Naranjo… - Omics: a journal of …, 2017 - liebertpub.com
A long-standing question and dilemma in precision medicine is whether and to what extent
genotyping or phenotyping drug metabolizing enzymes such as CYP2D6 can be used in …
genotyping or phenotyping drug metabolizing enzymes such as CYP2D6 can be used in …
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
Risperidone (R) is the most prescribed antipsychotic drug for patients with a first episode of
psychosis (FEP). In a naturalistic cohort of chronic psychiatric inpatients, we demonstrated …
psychosis (FEP). In a naturalistic cohort of chronic psychiatric inpatients, we demonstrated …
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina
A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype:
gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other …
gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other …
Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result
AL Arellano, M Martin-Subero, M Monerris, A LLerena… - Medicine, 2017 - journals.lww.com
3 Discussion As a result, no metabolic deficiencies for CYP2D6 were confirmed in the
pharmacogenetic test. The main reason that could explain those results could be the limited …
pharmacogenetic test. The main reason that could explain those results could be the limited …
Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
JB Larsen, JB Rasmussen - Pharmacogenomics and Personalized …, 2017 - Taylor & Francis
Due to their involvement in the metabolization of commonly prescribed
psychopharmaceutical drugs, the cytochrome oxidase genes CYP2D6 and CYP2C19 are …
psychopharmaceutical drugs, the cytochrome oxidase genes CYP2D6 and CYP2C19 are …
Genotyping CYP2D6 by three different methods: advantages and disadvantages
C Ribeiro, P Martins, M Grazina - Drug Metabolism and Personalized …, 2017 - degruyter.com
Background: CYP2D6 belongs to P450 superfamily, and is responsible for the metabolism of
25% of the drugs used clinically. Genetic variability of CYP2D6 affects individual drug or …
25% of the drugs used clinically. Genetic variability of CYP2D6 affects individual drug or …
[PDF][PDF] The AmpliChip CYP 450 Test: Personalized Medicine Has Arrived in Psychiatry
MD Jose de Leon - researchgate.net
The Food and Drug Administration (FDA) granted market approval for the first
pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, that genotypes the …
pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, that genotypes the …
Evaluación de la relevancia de factores farmacogenéticos, demográficos y de la patología cardiovascular en la utilización de servicios de salud en Atención Primaria
A Pijierro Amador - 2017 - dehesa.unex.es
INTRODUCCIÓN: Los polimorfismos genéticos del metabolismo en Fase I pueden dar lugar
a individuos con capacidad metabólica nula (Metabolizadores lentos ML) o anormalmente …
a individuos con capacidad metabólica nula (Metabolizadores lentos ML) o anormalmente …